[FOLFOX].
In metastatic colorectal cancer, a combination of Leucovorin (LV) and fluorouraci (l FU) with oxaliplatin (FOLFOX) is a standard first-line regimen. The two limiting toxicities of FOLFOX are neutropenia and the specific reversible sensory neuropathy of oxaliplatin. The cumulative neurotoxicity often requires therapy to be stopped. Immediate hypersensitive reactions (anaphylaxis) have been noted as often as to 0.6 percent. We should pay sufficient attention to side effects of FOLFOX.
Mishima
Hideyuki
H
National Hospital Organization, Osaka National Hospital.
Ikenaga
Masakazu
M
Tsujinaka
Toshimasa
T
Yasui
Masayoshi
M
Kashiwazaki
Masaki
M
Miyazaki
Michihiko
M
Hirao
Motohiro
M
Fujitani
Kazumasa
K
Nakamori
Shouji
S
D000707:Anaphylaxis / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D019983:Guideline Adherence; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D017410:Practice Guidelines as Topic
D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil